These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27884222)

  • 21. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease.
    Raij L
    Am J Hypertens; 2005 Apr; 18(4 Pt 2):95S-99S. PubMed ID: 15837551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant Rac1-mineralocorticoid receptor pathways in salt-sensitive hypertension.
    Kawarazaki W; Fujita T
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):929-36. PubMed ID: 24111570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.
    Albaghdadi M; Gheorghiade M; Pitt B
    Eur Heart J; 2011 Nov; 32(21):2626-33. PubMed ID: 21672933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Animal models of cardiorenal syndrome: a review.
    Szymanski MK; de Boer RA; Navis GJ; van Gilst WH; Hillege HL
    Heart Fail Rev; 2012 May; 17(3):411-20. PubMed ID: 21909828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic therapies for chronic and acute decompensated heart failure: specific insights on cardiorenal syndromes.
    Roubille F; Morena M; Leray-Moragues H; Canaud B; Cristol JP; Klouche K
    Blood Purif; 2014; 37 Suppl 2():20-33. PubMed ID: 25196566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework.
    Napoli C; Casamassimi A; Crudele V; Infante T; Abbondanza C
    Future Cardiol; 2011 Jul; 7(4):485-97. PubMed ID: 21797745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G; Ritz E
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What physicians need to know about renal function in outpatients with heart failure.
    Waldum-Grevbo B
    Cardiology; 2015; 131(2):130-8. PubMed ID: 25966919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of local and systemic angiotensin in diabetic renal disease.
    Anderson S
    Kidney Int Suppl; 1997 Dec; 63():S107-10. PubMed ID: 9407435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling.
    Di Zhang A; Nguyen Dinh Cat A; Soukaseum C; Escoubet B; Cherfa A; Messaoudi S; Delcayre C; Samuel JL; Jaisser F
    Hypertension; 2008 Dec; 52(6):1060-7. PubMed ID: 18981328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of angiotensin II in diabetic nephropathy.
    Kennefick TM; Anderson S
    Semin Nephrol; 1997 Sep; 17(5):441-7. PubMed ID: 9316212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular growth factors as potential new treatment in cardiorenal syndrome in diabetes.
    Ricciardi CA; Gnudi L
    Eur J Clin Invest; 2021 Sep; 51(9):e13579. PubMed ID: 33942293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pathophysiology and diagnosis of cardio-renal syndrome: actual picture and future prospectives].
    Di Lullo L; Floccari F; De Pascalis A; Marinelli A; Barbera V; Santoboni A; Malaguti M; Balducci A; Russo D; Rivera R; Gorini A; Ronco C
    G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin II receptors-antagonists, molecular biology, and signal transduction.
    Jagadeesh G
    Indian J Exp Biol; 1998 Dec; 36(12):1171-94. PubMed ID: 10093499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiorenal syndrome in chronic kidney disease.
    Tsuruya K; Eriguchi M
    Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):154-62. PubMed ID: 25636143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of a local renin angiotensin system in podocytes by glucose.
    Durvasula RV; Shankland SJ
    Am J Physiol Renal Physiol; 2008 Apr; 294(4):F830-9. PubMed ID: 18216149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biomarkers of cardiorenal syndrome].
    Kuster N; Moréna M; Bargnoux AS; Leray H; Chenine L; Dupuy AM; Canaud B; Cristol JP
    Ann Biol Clin (Paris); 2013; 71(4):409-18. PubMed ID: 23906568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of renal angiotensin type 1 receptor contributes to the pathogenesis of progressive renal injury in a rat model of chronic cardiorenal syndrome.
    Homma T; Sonoda H; Manabe K; Arai K; Mizuno M; Sada T; Ikeda M
    Am J Physiol Renal Physiol; 2012 Mar; 302(6):F750-61. PubMed ID: 22160776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.